# Armonica Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/armonica-technologies

- Industry: Biotechnology
- Headquarters: Carlsbad, US
- Website: www.armonicatech.com
- Total disclosed funding: $3.5M
- Latest round: Series B (Oct 8, 2021)
- Investors on record: 4

## About

Armonica Technologies, Inc. focuses on advancing genomic technologies that enhance research, diagnostics, therapeutics, and drug development through innovative methods and proprietary platforms.Founded in 2015 and headquartered in Carlsbad, US, Armonica Technologies, Inc. specializes in advanced genomic solutions. The company has successfully completed 4 deals, with its most recent funding round occurring on August 16, 2022. This round brought in USD 2.000 mn in grant funding from the National Human Genome Research Institute. The CEO, Victor Esch, leads this firm, which has yet to pivot from its original strategy or structure.Armonica Technologies specializes in advanced genomic technologies designed to improve research, diagnostics, therapeutics, and drug development. Its proprietary platform employs surface-enhanced Raman spectroscopy (SERS) to detect single nucleotides without DNA amplification, labels, or library preparation. This technology significantly enhances the identification of critical genomic data, addressing gaps in current genomic analysis, especially in epigenetic data and structural variants. The company integrates innovative metamaterial and plasmonic nanostructures into chips that manage particle velocity via electric fields, aiming to support precision medicine. Armonica primarily serves research institutions, healthcare providers, and pharmaceutical firms, focusing on markets in North America and Europe.Armonica Technologies generates revenue through collaborations with academic institutions, healthcare organizations, and biotech firms that utilize its SERS technology and related offerings. Its business model includes direct sales and potential subscription arrangements for ongoing access to its genomic analysis solutions. Revenue also comes from service agreements for research and development projects and licensing deals for proprietary technology applications. While specific pricing is undisclosed, the advanced capabilities of its flagship technology suggest a premium pricing structure for real-time genomic sequencing and detailed nucleic acid structure analysis, indicating a strong foundation for operational growth and market expansion.With the recent USD 2.000 mn grant funding received on August 16, 2022, from the National Human Genome Research Institute, Armonica Technologies plans to further develop its single-molecule long-read sequencing technology. The company aims to enhance its product offerings to better meet emerging market needs and expand its reach into new geographic regions, specifically targeting areas with established genomic research capabilities. By leveraging this funding, Armonica seeks to accelerate its growth initiatives and solidify its position in the genomic technology landscape.

## Funding rounds

- Series B, Oct 8, 2021, $2M — Sun Mountain Capital, Cottonwood Technology Fund, Hamamatsu Photonics K.K., Tramway Venture Partners
- Seed, Aug 21, 2017, $1.5M — Sun Mountain Capital, Cottonwood Technology Fund, Tramway Venture Partners

## Investors

- Sun Mountain Capital (https://capitalatlas.ai/funds/sun-mountain-capital) — Seed, Series B
- Cottonwood Technology Fund (https://capitalatlas.ai/funds/cottonwood-technology-fund) — Seed, Series B
- Tramway Venture Partners (https://capitalatlas.ai/funds/tramway-venture-partners) — Seed, Series B
- Hamamatsu Photonics K.K. — Series B